『WolverHeme Happy Hour』のカバーアート

WolverHeme Happy Hour

WolverHeme Happy Hour

著者: Bernard Marini Anthony Perissinotti et al.
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.Bernard Marini, Anthony Perissinotti, et al. 衛生・健康的な生活 身体的病い・疾患
エピソード
  • VAR Review with Dr. Bixby: Reversing the Call on MPAL
    2026/07/01

    In this episode, Anthony and Bernie are joined by the great Dr. Bixby to discuss the difficulties in the diagnosis and treatment of acute leukemias of mixed or ambiguous lineage (ALAL/MPAL).

    We discuss:

    - Diagnostic uncertainties and how the criteria for diagnosis have changed over the years

    - Data behind the optimal treatment of MPAL and uncertainties in the literature

    - Promising data for the FLAG-VIPR hybrid regimen and other novel treatment strategies

    続きを読む 一部表示
    1 時間 7 分
  • Bispecifics ate CAR-T's lunch: a multiple myeloma debate
    2026/06/11

    In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispecifics? How does the new mezigdomide data from ASCO 2026 inform our practice? Listen in for a spicy discussion!


    Articles discussed:

    • Nature Reviews Commentary: https://www.nature.com/articles/s41571-026-01159-6
    • CARTITUDE-4: https://www.nature.com/articles/s41571-026-01159-6
    • MajesTEC-3: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663
    • MajesTEC-9: https://www.nejm.org/doi/abs/10.1056/NEJMoa2603870
    • Control arms in multiple myeloma trials: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026020329/567836/Improving-Control-Arms-in-2026-U-S-Myeloma-Trials
    • Predictors for CAR T cell therapy-associated immune-related adverse events? https://pubmed.ncbi.nlm.nih.gov/41540109/
    • Dex prophylaxis for lymphocytosis: https://ashpublications.org/bloodadvances/article/10/10/3629/567462/Dexamethasone-prophylaxis-for-excessive-lymphocyte
    • Mezi-KD vs. KD ASCO 2026: https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA7506
    続きを読む 一部表示
    56 分
  • Episode 47: Cult-Like Thinking in BMT
    2026/06/04

    “However much we flatter ourselves about our individual rationality, a good story, no matter how analytically deficient, lingers in the mind, resonates emotionally, and persuades more than the most dispositive facts or data.”

    Inspired by the article "The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers" (https://www.nature.com/articles/s41409-021-01473-w), in this episode, Anthony and Bernie are joined by transplant experts Tate Feeney, PharmD, BCOP and Aaron "Papa heme" Goodman, MD, to discuss "cult-like thinking" in hematology and BMT. We discuss why this occurs, go through some provocative examples, and talk about how to identify bias or ”cult-like thinking” in our own practices!

    Grab your favorite drink and prepare to join the wolverheme cult!

    続きを読む 一部表示
    45 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません